The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BioNTech (I); GANYMED Pharmaceuticals
Leadership - BioNTech (I); GANYMED Pharmaceuticals
Stock and Other Ownership Interests - BioNTech (I)
Consulting or Advisory Role - GANYMED Pharmaceuticals
Patents, Royalties, Other Intellectual Property - BioNTech (I); GANYMED Pharmaceuticals
 
Leadership - Institut für Klinische Krebsforschung GmbH
Honoraria - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; Miami Cancer Institute; Nordic Bioscience; Promedior; Roche
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
 
Ugur Sahin
Leadership - BioNTech; GANYMED Pharmaceuticals (I)
Stock and Other Ownership Interests - BioNTech
Consulting or Advisory Role - GANYMED Pharmaceuticals
Patents, Royalties, Other Intellectual Property - BioNTech; GANYMED Pharmaceuticals (I)
 
Özlem Tureci
No Relationships to Disclose
 
Georgy M. Manikhas
No Relationships to Disclose
 
Florian Lordick
Honoraria - AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Infomedica; Lilly; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Andriy Rusyn
No Relationships to Disclose
 
Ihor Vynnychenko
No Relationships to Disclose
 
Assen Dudov
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - Roche
 
Igor Bazin
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Bohuslav Melichar
Honoraria - Acraf; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eliamm; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi
 
Karl Dhaene
No Relationships to Disclose
 
Kai Wiechen
Honoraria - GANYMED Pharmaceuticals
 
Daniel Maurus
No Relationships to Disclose
 
Martin H. Schuler
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Salah-Eddin Al-Batran
No Relationships to Disclose